25
Jul
2024
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jul
2024
Attia and Kohane Examine What It Takes To Drive AI into Clinical Practice
Peter Attia is a prominent physician-turned-California longevity guru, and (to paraphrase Woody Allen) as California longevity gurus go, he’s one of the best, striving to remain grounded in science and data. Known for his popular book Outlive, and his affection for “rucking” (look it up), Attia is also the host of a long-form podcast called The Drive, and an engaging... Read More
16
Jul
2024
Biologic Drug Discovery With AI: Sean McClain on The Long Run
Sean McClain is today’s guest on The Long Run. He’s the founder and CEO of Vancouver, Washington-based Absci. Sean started the company on his own in his early 20s, straight out of the University of Arizona, with the encouragement of his Dad. You could call it a scrappy garage biotech, with no traditional VC backers at first. He found a... Read More
14
Jul
2024
AI: If Not Now, When? No, Really — When?
“It was all mixed into one, enormous, overflowing stew of very real technological advances, unfounded hype, wild predictions, and concerns for the future. ‘Artificial intelligence’ was the term that described it all.” – Cade Metz, Genius Makers The buzzy excitement around artificial intelligence (AI), and most recently generative artificial intelligence (genAI), has inspired some biopharma leaders, exasperated many others,... Read More
11
Jul
2024
Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jun
2024
A Long-Lasting Drug Against Flu: Jeff Stein on The Long Run
Jeff Stein is today’s guest on The Long Run. He’s the CEO of San Diego-based Cidara Therapeutics. Jeff has led teams that have successfully developed a novel antibiotic, and a novel antifungal, all the way through FDA approval. This latest project with an antiviral could be the most important of his career. Cidara has a platform for making drug-Fc conjugate... Read More
25
Jun
2024
Exsilio Gets $82M to Make mRNA Therapies That Integrate and Endure
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jun
2024
On Juneteenth, Recognizing 18 Black Biopharma Industry Leaders
Ken Frazier, Tony Coles, Rob Perez and Ted Love are among the biggest names in the biopharma industry. They also happen to be Black. But there are many other Black people making significant contributions, and who aren’t so widely known. Let’s recognize some of these folks today on the Juneteenth holiday. On June 19, 1865 — long after the Emancipation... Read More
18
Jun
2024
Marea, Incubated by Third Rock, Gets $190M to Take Aim at Remnant Cholesterol
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2024
Precision Neuroscience for Epilepsy and More: Abe Ceesay on The Long Run
Abe Ceesay is today’s guest on The Long Run. He’s the CEO of Boston-based Rapport Therapeutics. Rapport started with a $100 million Series A financing in March 2023 from Third Rock Ventures, Arch Venture Partners and Johnson & Johnson Innovation. As the company name subtly suggests, it’s based on biology of R A Ps, or receptor-associated proteins. The idea is... Read More
13
Jun
2024
Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2024
Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jun
2024
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jun
2024
A New Outlook on Life With Sickle Cell Disease: Jimi Olaghere on The Long Run
Today’s guest on The Long Run is Jimi Olaghere. His story will take your breath away. Jimi was born with sickle cell disease. He suffered from severe pain episodes, fatigue and shortness of breath through much of his life. Then in September 2020, he enrolled in a clinical trial when he got the CRISPR-gene edited therapy known as exa-cel, or... Read More
30
May
2024
Merck Bets on the Eye, Merus Raises a Fortune, & Roche Leadership Change
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
May
2024
Recognizing 11 Asian-American Executives Shaping the Future of Biopharmaceuticals
As we celebrate the end of AAPI Heritage Month, we acknowledge the vital role that Asian American and Pacific Islander professionals have made in the biopharmaceutical industry. We are honored to present an update to our 2021 feature on 11 AAPI professionals shaping the future of biopharma, again selected for their commitment to solving health problems, integrity in leadership, and... Read More
29
May
2024
On The Bright Side: Better Medicines, Shared Purpose, Good Listens
While visiting my parents on Memorial Day weekend, I reflected on the wonder and joy of a life in medicine and science — theirs as well as mine. Incredible Progress in Medicine My parents are academic physician-scientists at Yale Medical School, where they founded and continue to lead the Yale Center for Dyslexia and Creativity. Now in their early 80s,... Read More
26
May
2024
The Tao of Drucker: Lessons For Drug Developers from GLP-1
The two broad categories of medical discovery that command the most attention are insights resulting from rare, informative genetic conditions (see here) and advances resulting from fortuitous observations. A canonical example of the value of extreme genetic phenotypes is the patient with familial hypercholesterolemia who inspired Brown and Goldstein’s scientific pursuit of cholesterol metabolism and led to the statins. Similarly,... Read More
23
May
2024
Biogen Buys HI-Bio, Endeavor Reverses Lung Scarring, & Pfizer’s Latest Cuts
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2024
SixPeaks Snags $110M from Versant, AZ for Drugs to Preserve Muscle and Shed Fat
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.